KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Current Deferred Revenue (2017 - 2025)

Historic Current Deferred Revenue for Neogenomics (NEO) over the last 9 years, with Q4 2025 value amounting to $1.2 million.

  • Neogenomics' Current Deferred Revenue rose 6604.03% to $1.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 million, marking a year-over-year increase of 6604.03%. This contributed to the annual value of $1.2 million for FY2025, which is 6604.03% up from last year.
  • According to the latest figures from Q4 2025, Neogenomics' Current Deferred Revenue is $1.2 million, which was up 6604.03% from $2.1 million recorded in Q3 2025.
  • Neogenomics' Current Deferred Revenue's 5-year high stood at $7.6 million during Q4 2022, with a 5-year trough of $745000.0 in Q4 2024.
  • Moreover, its 5-year median value for Current Deferred Revenue was $4.2 million (2021), whereas its average is $4.0 million.
  • Per our database at Business Quant, Neogenomics' Current Deferred Revenue tumbled by 8114.39% in 2024 and then surged by 11147.21% in 2025.
  • Over the past 5 years, Neogenomics' Current Deferred Revenue (Quarter) stood at $6.1 million in 2021, then grew by 24.01% to $7.6 million in 2022, then plummeted by 71.88% to $2.1 million in 2023, then plummeted by 65.02% to $745000.0 in 2024, then soared by 66.04% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q4 2025, $2.1 million for Q3 2025, and $1.5 million during Q2 2025.